LUMO Lumos Pharma Corp: Net Assets per Single Share

Symbol and logo of brand Lumos Pharma, Inc. (LUMO)

Lumos Pharma, Inc. (LUMO) develops convenient oral medications for children with hormonal deficiencies. The trust of geneticists confirms the value of these innovations, and on GURU.Markets, the book value per share trend clearly links market potential with brand reputation. The current 0.57 metric determines the parameter status, while the R&D stage and rising research costs temporarily limit business scaling.

LUMO Lumos Pharma Inc Share Book Value (07/04/2022 - 12/21/2024)

Summary analytical data breakdowns for lumos-pharma.com (LUMO)

- current quotes and average value forecast:
Price Chart Lumos Pharma Corp|LUMO - Consensus Target
- company stock capitalization data:
Market Value Lumos Pharma, Inc.|LUMO - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share Lumos Pharma|LUMO - Net Asset Value|Market Capitalization to Book Value Ratio lumos-pharma.com|LUMO - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Lumos Pharma, Inc.|LUMO - Long-Term Debt to Capital|Short-Term Debt to Equity Lumos Pharma|LUMO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Lumos Pharma, Inc.|LUMO - Company Long-Term Liabilities|Company Short-Term Debts Lumos Pharma
General company analysis:LUMO - Lumos Pharma Corp
Manufactured products of Lumos Pharma

Book value per share allows investors to filter out market volatility by measuring the company's net equity minus all liabilities to assess the business's intrinsic stability. By analyzing the historical trend of the book value per share, an investor can discern the actual volume of assets held by Lumos Pharma (LUMO), the reliability of which is bolstered by diversified raw material supply chains that guarantee the continuity of drug development for metabolic disorders.

Competitor analysis

ASND - Net Assets per Single Share|Madrigal Corp (MDGL) - Accounting Value per Share|Corcept Therapeutics (CORT) - Net Assets per Single Share|Net Asset Value per Share rhythmtx.com (RYTM)|Net Assets per Single Share Akero|Metsera, Inc. - Share Book Value|Book Value per Share MLTX|CRNX (Crinetics Corp) - Accounting Value of a Share|Book Value per Share NAMS (NewAmsterdam Pharma)|Book Value per Share soleno.life SLNO|FOLD - Net Assets per Single Share|Accounting Value of a Share ETNB (89bio Inc)|Agios Pharmaceuticals Inc (AGIO) - Net Assets per Single Share|Accounting Value per Share Structure Corp|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com|Accounting Value per Share LXRX (Lexicon Pharmaceuticals, Inc.)|MBX (MBX Biosciences, Inc.) - Accounting Value of a Share|Net Assets per Single Share Altimmune Corp ALT|AARD - Accounting Value per Share|Sagimet Biosciences - Book Value per Share|Net Asset Value per Share bioagelabs.com|BMEA (Biomea Fusion) - Accounting Value per Share|QNCX: Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share vTv Therapeutics Inc|Book Value per Share ATPC|Net Assets per Single Share PLUR (pluri-biotech.com)|Net Assets per Single Share Synlogic SYBX|Lipocine Inc (LPCN) - Net Asset Value per Share|MTNB - Net Assets per Single Share|SPRB: Net Assets per Single Share|GLTO: Book Value per Share|CTCX - Net Assets per Share|Net Assets per Single Share Organovo|Radius Recycling Inc. (RDUS) - Net Assets per Share